Business Standard

Lupin gets USFDA nod to market oral contraceptive

The sales of the tablet were approximately $103.6 million in the US market

Viveat Susan Pinto  |  Mumbai 

  • ALSO READ

    Aurobindo Pharma gets US nod for anti-bacterial injections Aurobindo gets USFDA approval for hypertension drug Strong US portfolio to help Lupin sustain growth Strong US portfolio to help Lupin sustain growth Pharma sector growth falls

Pharma major Ltd has received the final approval from the United States Food and Drugs Administration (USFDA) to market a generic version of an oral conceptive called Lutera Tablets.

The sales of the tablet were approximately $103.6 million in the US market and Lupin will begin marketing the generic version shortly, the company said.

Lupin is the fifth largest generics player in the US with a share of 5.1%. It is a significant player in the cardiovascular, diabetology, asthma and pediatric segments, holding global leadership in the anti-tuberculosis area.

RECOMMENDED FOR YOU

Lupin gets USFDA nod to market oral contraceptive

The sales of the tablet were approximately $103.6 million in the US market

Pharma major Lupin Ltd has received the final approval from the United States Food and Drugs Administration (USFDA) to market a generic version of an oral conceptive called Lutera Tablets.

Pharma major Ltd has received the final approval from the United States Food and Drugs Administration (USFDA) to market a generic version of an oral conceptive called Lutera Tablets.

The sales of the tablet were approximately $103.6 million in the US market and Lupin will begin marketing the generic version shortly, the company said.

Lupin is the fifth largest generics player in the US with a share of 5.1%. It is a significant player in the cardiovascular, diabetology, asthma and pediatric segments, holding global leadership in the anti-tuberculosis area.

image
Advertisement